<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639817</url>
  </required_header>
  <id_info>
    <org_study_id>BD022382</org_study_id>
    <nct_id>NCT04639817</nct_id>
  </id_info>
  <brief_title>Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study</brief_title>
  <official_title>Trimethoprim-Sulfamethoxazole or Levofloxacin? A Retrospective Cohort Study of Targeted Therapy for Stenotrophomonas Maltophilia Blood Stream and Lower Respiratory Tract Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to compare mortality outcomes of levofloxacin and&#xD;
      trimethoprim-sulfamethoxazole treated patients who have Stenotrophomonas maltophilia blood&#xD;
      stream or lower respiratory tract infections by retrospectively analyzing a&#xD;
      propensity-matched cohort from a large dataset of electronic health record data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Actual">April 27, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death or hospice discharge</measure>
    <time_frame>In-hospital</time_frame>
    <description>Patient died or discharged to hospice</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Single encounter</time_frame>
    <description>Mean hospital length of stay, where mortality will be censored as longest possible length of stay</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1621</enrollment>
  <condition>Stenotrophomonas Infection</condition>
  <arm_group>
    <arm_group_label>Levofloxacin targeted therapy</arm_group_label>
    <description>Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received Levofloxacin from day of culture positivity (day 0) through day +7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMP/SMX targeted therapy</arm_group_label>
    <description>Patients with Stenotrophomonas maltophilia bacteremia or lower respiratory tract infection who received TMP/SMX from day of culture positivity (day 0) through day +7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin administration</description>
    <arm_group_label>Levofloxacin targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole</intervention_name>
    <description>Trimethoprim-sulfamethoxazole administration</description>
    <arm_group_label>TMP/SMX targeted therapy</arm_group_label>
    <other_name>TMP/SMX</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult inpatients with Stenotrophomonas maltophilia blood stream or lower respiratory tract&#xD;
        infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Stenotrophomonas maltophilia culture positive from blood or the following specified&#xD;
             respiratory tract sites: sputum, tracheal aspirate, bronchoalveolar lavage and&#xD;
             protected bronchial brush washings&#xD;
&#xD;
          -  Received either levofloxacin or TMP/SMX targeted therapy&#xD;
&#xD;
          -  Those patients that received empiric therapy with a consistent medication (for&#xD;
             example, levofloxacin empirically in the levofloxacin targeted therapy cohort) were&#xD;
             included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received antimicrobial other than TMP/SMX and levofloxacin, with known activity&#xD;
             against Stenotrophomonas maltophilia (the list of antimicrobials that fit this&#xD;
             exclusion criteria is: erythromycin, moxifloxacin, ciprofloxacin, minocycline,&#xD;
             tigecycline, doxycycline, eravacycline, ceftazidime, cefepime,&#xD;
             ticarcillin-clavulanate, cefiderocol, colistin, and chloramphenicol)&#xD;
&#xD;
          -  Received inconsistent empiric therapy (for example, levofloxacin empirically in the&#xD;
             TMP/SMX targeted therapy cohort) will be excluded from analysis&#xD;
&#xD;
          -  Cystic fibrosis code present&#xD;
&#xD;
          -  Organism resistant to therapy received&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameer Kadri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Sameer Kadri, M.D.</investigator_full_name>
    <investigator_title>Staff Clinician, Critical Care Medicine Department</investigator_title>
  </responsible_party>
  <keyword>Stenotrophomonas maltophilia, Stenotrophomonas, Levofloxacin, TMP/SMX, Trimethoprim-sulfamethoxazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>N/A, this data is deidentified</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT04639817/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

